"Official medicines" is the best online drugstore.World’s leading meds delivered to your door – and you don’t even need a prescription! Only certified, first class drugs on offer! Buy more and spend less with our great discount system. The meds you need, reliable and hassle free! Top products of top brands.The only pharmacy shop you will ever need! Approved drugs available without prescription. Best deals, unmatched service and shipping. 100% safe! |
| (klor-DIE-aze-ee-POX-ide) |
Libritabs, Librium, Mitran, Reposans-10, Solium |
| Class: Antianxiety/benzodiazepine |
Action Potentiates action of GABA to produce CNS depression.
Indications Management of anxiety disorders; relief of acute alcohol withdrawal symptoms; relief of preoperative apprehension and anxiety. Unlabeled use(s): Treatment of irritable bowel syndrome.
Contraindications Hypersensitivity to benzodiazepines; psychoses; acute narrow-angle glaucoma; shock; coma; acute alcohol intoxication.
Individualize dosage. Acute symptoms may be rapidly controlled IM or IV, with subsequent oral treatment (maximum 300 mg/day).
Mild-to-Moderate Anxiety
ADULTS: PO 5–10 mg tid or qid.
Severe Anxiety
ADULTS: PO 20–25 mg tid or qid. Initial dose: IM/IV 50–100 mg, then 25–50 mg tid or qid. ELDERLY OR DEBILITATED PATIENTS: PO 5 mg bid to qid. IM/IV 25–50 mg.
Preoperative Apprehension/Anxiety
ADULTS: PO 5–10 mg tid or qid on days preceding surgery. IM 50–100 mg 1 hr prior to surgery.
Acute Alcohol Withdrawal
ADULTS: IM/IV 50–100 mg; repeat q 2–4 hr prn. PO 50–100 mg, repeat prn (maximum oral or parenteral dose is 300 mg/day). CHILDREN (> 6 YR): PO 5–10 mg bid-qid; may be increased to 10 mg bid-tid. CHILDREN (> 12 YR): IM 0.5 mg/kg/day 6–8 hr.
Alcohol and CNS depressants: Additive CNS depressant effects are possible. Cigarette smoking, theophyllines: May antagonize sedative effects. Cimetidine, oral contraceptives, disulfiram, omeprazole: May increase effects of chlordiazepoxide with excessive sedation and impaired psychomotor function. Digoxin: May increase serum digoxin concentrations.
Lab Test Interferences None well documented.
CV: Cardiovascular collapse; hypotension; hypertension; tachycardia; bradycardia; edema; phlebitis or thrombosis at IV sites. CNS: Drowsiness; confusion; ataxia; dizziness; fatigue; apathy; memory impairment; disorientation; anterograde amnesia; restlessness; headache; slurred speech; loss of voice; stupor; coma; euphoria; irritability; vivid dreams; psychomotor retardation; paradoxical reactions (eg, anger, hostility, mania, insomnia, muscle spasms). DERM: Rash. EENT: Visual or auditory disturbances; depressed hearing. GI: Constipation; diarrhea; dry mouth; coated tongue; nausea; anorexia; vomiting. HEMA: Blood dyscrasias including agranulocytosis; anemia; thrombocytopenia; leukopenia; neutropenia. HEPA: Abnormal liver function tests; hepatic dysfunction including hepatitis and jaundice. OTHER: Dependency/withdrawal syndrome.
Pregnancy: Category D. Avoid especially in first trimester due to possible increased risk of congenital malformations. Lactation: Excreted in breast milk. Children: Initial dose should be small and gradually increased. Oral form not recommended in children < 6 yr; parenteral form not recommended in children < 12 yr. Elderly or debilitated patients: Initial dose should be small and gradually increased. Use with caution in patients with limited pulmonary reserve. Dependency: Prolonged use can lead to dependency. Withdrawal syndrome has occurred within 4–6 wk of treatment, especially if drug is abruptly discontinued. For discontinuation after long-term treatment, use caution and taper dosage. Psychiatric disorders: Not intended for patients with primary depressive disorder, psychosis or disorders in which anxiety is not prominent. Parenteral administration: Reserved primarily for acute states. Renal or hepatic impairment: Observe caution to avoid accumulation of drug. Suicide: Use with caution in patients with suicidal tendencies; do not allow patient access to large quantities of drug.
| PATIENT CARE CONSIDERATIONS |
|
|
||||
Popularity: 2% [?]
RSS feed for comments on this post · TrackBack URI
Leave a reply